Stereotactic radiosurgery (SRS) in combination with immunotherapy (IT) is increasingly used in the setting of melanoma and non-small cell lung cancer (NSCLC) brain metastases (BM). The synergistic properties of this treatment combination are still not deeply understood. IT-SRS appropriate combination has been envisioned as a strategic point in patients’ management.

Authors performed a systematic review on current evidences up to December 2020. The impact of SRS-IT and different IT schedules on survival, local/distant intracranial control and toxicity, as well as predictive factors for relevant oncological and radiological outcomes has been analyzed.

Authors retrieved 23 pertinent studies. Combining SRS with IT resulted in a significant improvement in OS and lesion response with no increase in radionecrosis, hemorrhage or other complications.

The present review suggests that combining IT to SRS is safe and effective in providing a significant improvement in relevant clinical and radiological outcomes in melanoma and NSCLC BMs patients.

立体定向放射外科 (SRS) 联合免疫疗法 (IT) 越来越多地用于治疗黑色素瘤和非小细胞肺癌 (NSCLC) 脑转移 (BM)。这种治疗组合的协同特性仍未深入了解。IT-SRS 的适当组合已被设想为患者管理的战略要点。

作者对截至 2020 年 12 月的当前证据进行了系统评价。分析了 SRS-IT 和不同 IT 计划对生存、局部/远处颅内控制和毒性的影响，以及相关肿瘤学和放射学结果的预测因素。

作者检索了 23 项相关研究。将 SRS 与 IT 相结合，显着改善了 OS 和病变反应，而没有增加放射性坏死、出血或其他并发症。

本综述表明，将 IT 与 SRS 相结合可安全有效地显着改善黑色素瘤和非小细胞肺癌患者的相关临床和放射学结果。